Putnam Investments’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Putnam Investments’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-161,531	Closed	-$1.66M	–	1299
2016 Q4	$1.66M	Hold	161,531	–	–	﹤0.01%	884
2016 Q3	$1.63M	Sell	161,531 -1,600	-1%	-$17.5K	﹤0.01%	900
2016 Q2	$1.83M	Hold	163,131	–	–	﹤0.01%	956
2016 Q1	$2.23M	Hold	163,131	–	–	0.01%	919
2015 Q4	$3.1M	Hold	163,131	–	–	0.01%	850
2015 Q3	$3.06M	Hold	163,131	–	–	0.01%	853
2015 Q2	$2.43M	Hold	163,131	–	–	﹤0.01%	996
2015 Q1	$2.47M	Hold	163,131	–	–	﹤0.01%	992
2014 Q4	$2.17M	Hold	163,131	–	–	﹤0.01%	1002
2014 Q3	$2.06M	Hold	163,131	–	–	﹤0.01%	1011
2014 Q2	$1.65M	Hold	163,131	–	–	﹤0.01%	1076
2014 Q1	$2.19M	Buy	+163,131	New	+$2.3M	0.01%	1027

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Putnam Investments's CNCE Position: Q1 2017 in Review

Putnam Investments sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017, closing a stake of 161,531 shares — an estimated $1.66M sold.

Putnam Investments first reported a position in CNCE in Q1 2014 and held it in 12 quarters. The position peaked at $3.1M in Q4 2015. 85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

Putnam Investments reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Putnam Investments sold 161,531 Concert Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.66M.
Putnam Investments first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 12 quarters.
Putnam Investments's Concert Pharmaceuticals, Inc. position peaked at $3.1M in Q4 2015.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on Putnam Investments's 13F filing for Q1 2017, filed 15 May 2017.